For the study, Morgans and her coauthors evaluated data for 284 patients. Of the cohort, 37% had known PSADT and 63% had unknown PSADT. More patients with known PSADT had characteristics of more ...

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

"It is important for us to ask patients whether they want to intensify or not, and not make assumptions," says Alicia Morgans, MD, MPH. In this video, Alicia Morgans, MD, MPH, shares insights from the ...

"It was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer," says Dr Louise Kostos. In this video, Dr ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...

"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS. Moyer: Since nadofaragene firadenovec was approved in ...

“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching, MD. In this interview, Christina ...

Experts discuss the frequency of cystectomy use in patients with non–muscle-invasive bladder cancer (NMIBC) and how often patients are requesting bladder-sparing treatments.

"[The lack of] a battery makes it ultra small. That's really important," says Colin Goudelocke, MD. In this video, Colin Goudelocke, MD, describes the advantages of a batteryless neurostimulator ...

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...

ChRCC originates from distal tubule α-intercalated cells, differing from clear cell and papillary kidney cancers. ChRCC shows downregulation of antigen-presenting machinery, indicating immune evasion ...

"[Urologists] really need to understand how big the prostate is and how big of a surgery that they're looking at," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her perspective ...